Idt Biologika
Idt Biologika GmbH, a prominent player in the biopharmaceutical industry, is headquartered in Dessau-Rosslau, Germany, with significant operations across Europe and North America. Founded in 1921, the company has established itself as a leader in the development and manufacturing of vaccines and biopharmaceuticals, focusing on innovative solutions for public health. Idt Biologika's core offerings include contract development and manufacturing services (CDMO) for vaccines, as well as advanced therapies. Their unique capabilities in viral vector production and fill-finish services set them apart in a competitive market. With a commitment to quality and regulatory compliance, Idt Biologika has achieved notable milestones, including partnerships with major pharmaceutical companies and contributions to global vaccination efforts. This positions them as a trusted partner in the biopharmaceutical landscape.
DitchCarbon Score
How does Idt Biologika's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Development industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Idt Biologika's score of 33 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Idt Biologika's reported carbon emissions
In 2023, IDT Biologika reported carbon emissions of approximately 8.4 million tonnes CO2e for Scope 1 and about 7.2 million tonnes CO2e for Scope 2. This reflects a slight decrease in Scope 1 emissions compared to 2022, where emissions were around 8.4 million tonnes CO2e, while Scope 2 emissions saw a significant reduction from approximately 12.2 million tonnes CO2e in 2022. IDT Biologika is committed to achieving net-zero emissions across all scopes by 2050, as part of their long-term climate strategy. This commitment aligns with the Science Based Targets initiative (SBTi), which underscores their dedication to reducing their carbon footprint in the pharmaceutical, biotechnology, and life sciences sector. The company has set a start year of 2023 for its net-zero journey, demonstrating proactive engagement in climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 8,443,450 | 0,000,000 | 0,000,000 |
| Scope 2 | 12,228,900 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Idt Biologika is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
